Overview

* Personalis ( PSNL ) Q3 revenue beats analyst expectations despite a 44% yr/yr decline

* Net loss for Q3 2025 was $21.7 mln, compared to $39.1 mln last year

* Clinical test volume grows 364% yr/yr, driven by NeXT Personal platform adoption

Outlook

* Personalis expects Q4 2025 revenue between $15.7 mln and $20.7 mln

* Full-year 2025 revenue guidance revised to $68.0 mln to $73.0 mln

* Company maintains full-year gross margin guidance at 22% to 24%

Result Drivers

* CLINICAL TEST GROWTH - Clinical test volume grew 364% yr/yr, driven by increased adoption of NeXT Personal platform

* LUNG CANCER DATA - Presentation of positive data from AstraZeneca's NeoADAURA trial and LAURA trial supports NeXT Personal's effectiveness in lung cancer

* BREAST CANCER STUDY - Launch of CATE trial with Yale Cancer Center aims to demonstrate NeXT Personal's utility in HR+/HER2- breast cancer

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $14.49 $13.30

Revenue mln mln (7

Analysts

)

Q3 Net -$21.65

Income mln

Q3 Basic -$0.24

EPS

Q3 -$23.29

Income mln

From

Operatio

ns

Q3 -$21.64

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Personalis Inc ( PSNL ) is $7.00, about 28.6% below its November 3 closing price of $9.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)